or Try an Advanced Search...

    ETF Components for MNTL - Tema Neuroscience and Mental Health ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    VRTX B -0.74 5.83
    LLY B -0.95 5.36
    REGN B -1.97 4.80
    BIIB C -1.84 4.68
    NBIX C 0.54 4.46
    SYK C -0.68 3.90
    DNLI C -2.02 3.73
    ARGX B -0.05 3.58
    TEVA B 1.63 3.43
    DXCM F -1.40 3.35

    Represented by ETF Holdings

    Keywords: S&P 500 Medicine Nasdaq 100 Pain Alzheimer's Disease Biopharmaceutical Cholesterol Diabetes Lymphoma Asthma Autoimmune Disease Biotechnology Breakthrough Therapy Cancer Cardiovascular Disease Chronic Lymphocytic Leukemia Clinical Development Degenerative Disease Disorders Endocrinology
    Industries: Biotechnology Drug Manufacturers - Major Diagnostics & Research Drug Manufacturers - Specialty & Generic Medical Devices

    Recent News for Tema Neuroscience and Mental Health ETF & its Holdings

    Date Stock Title
    Jul 3 LLY Lilly's new Alzheimer's drug could generate $7.1B in sales: analyst
    Jul 3 LLY S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
    Jul 3 BIIB Top Stock Movers Now: Tesla, Paramount Global, Biogen, and More
    Jul 3 LLY Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
    Jul 3 LLY Weight-loss drugs linked to rare vision loss: Harvard study
    Jul 3 LLY ADP jobs data, Constellation Brands, summer gas prices: Morning Brief
    Jul 3 LLY Ozempic Linked to Rare Cases of Vision Loss in Harvard Study
    Jul 3 DXCM DexCom's ADA Conference Takeaways: Stelo, CGM Tailwinds Still Intact
    Jul 3 LLY FDA Approves Eli Lilly's Alzheimer's Drug Kisunla
    Jul 3 BIIB Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence
    Jul 3 LLY Top 3 Health Care Stocks That May Crash This Quarter
    Jul 3 REGN Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
    Jul 3 LLY Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
    Jul 3 REGN Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
    Jul 3 LLY 5 Things to Know Before the Stock Market Opens
    Jul 3 SYK Should You Investigate Stryker Corporation (NYSE:SYK) At US$334?
    Jul 3 LLY Eli Lilly Advances Alzheimer's Solutions With Kisunla Approval
    Jul 3 REGN Sanofi, Regeneron win EU label expansion for Dupixent in COPD
    Jul 3 LLY Eli Lilly Shares Gain After Drug-Maker Gets FDA's Nod For Early Alzheimer's Treatment
    Jul 3 REGN Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
    Under normal circumstances, the Tema Neuroscience and Mental Health ETF seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in neuroscience and mental health companies. A company is generally considered to be a neuroscience or mental health company that derives at least 50% of revenues from neuroscience or neurology-related diseases, or mental health. The fund is non-diversified.
    Neuroscience Neurophysiology Neurology Nervous System
    Back to the Main MNTL Page...